Sesen Bio, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas R. Cannell D.V.M.
- Full Time Employees
- 17
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 245 First Street Cambridge MA United States of America 02142
- IPO Date
- Feb 6, 2014
- CIK
- 0001485003
- Website
- sesenbio.com
- Similar Companies
- Business
- Sesen Bio, Inc. (SESN) is a late-stage clinical-stage biotechnology company that designs, engineers, develops and commercializes targeted fusion protein therapeutics for the treatment of cancer. The company offers Vicineum, a locally administered fusion protein targeting EpCAM for high-grade non-muscle invasive bladder cancer in patients previously treated with BCG; Proxinium, targeting the same antigen for squamous cell carcinoma of the head and neck; and VB6-845d, an anti-EpCAM fusion protein for epithelial cell adhesion molecule-positive solid tumors; utilizing its proprietary platform of recombinant fusion proteins produced via a one-step microbial manufacturing process that binds tumor cell surface antigens for rapid internalization with limited expression on normal cells. Founded in 2004 and headquartered in Cambridge, Massachusetts, Sesen Bio previously operated primarily in the United States with a focus on oncology indications suffering high unmet medical needs, including bladder cancer representing over 80,000 new U.S. cases annually. In March 2023, Sesen Bio completed a merger with Carisma Therapeutics Inc., under which it became part of the combined entity operating as Carisma Therapeutics (NASDAQ: CARM) headquartered in Philadelphia, Pennsylvania, with SESN shares continuing to trade post-merger alongside a $75 million special cash dividend to Sesen stockholders and $30 million concurrent financing providing runway through 2024; the deal included contingent value rights tied to potential proceeds from legacy assets like Vicineum and a Roche milestone, marking a strategic shift from bladder cancer fusion proteins toward Carisma's engineered macrophage immunotherapy platform.
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting
Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger
BML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics
Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger
Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger
Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger
Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger
Sesen Bio Receives NASDAQ Delisting Notice
Sesen Bio Receives NASDAQ Delisting Notice
Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders
Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders
Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support
Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support